Inderes delivered 7% sales growth in April, slightly ahead of our 5% estimate.
* Q1 lower than expected * Estimates down given a lower AUM base * Capital repatriation will help to...
Redeye comments on Camurus' Q1 report 2026, which was below our estimates due to lower revenues from...
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Vi inleder bevakning på K-Fastigheter, ett snabbväxande entreprenad- och fastighetsbolag med fokus p...
Redeye comments on Fable Media Group’s Q1 2026 results, which came in below our estimates on both re...
Relais Q1 adjusted EBITA of EUR 12.8m was up 40% y/y and came 5% above Modular Finance consensus of ...
Administer's Q1 results came in clearly below our expectations, with net sales declining 6% and EBIT...
Siljansvik delivered a strong Q1 report with improved earnings across all major holdings and continu...
Svag bruttomarginal pressade resultatet Nettoomsättningen ökade med 6,1 % till 120,2 MSEK (113,3), ...
Following its listing on the LSE Main Market in October 2025, Cindrigo has now moved into an executi...
Redeye provides its first take on Oncopeptides' Q1 report 2026.
Redeye retains its positive view of Transtema despite a softer-than-expected Q1.
The takeaway from Eckert & Ziegler’s Q1 results is positive: Medical delivered strong underlying gro...
Redeye returns with an update following SciBase Holding’s Q1 report, which largely met our expectati...
* Volumes stronger than expected * Gross margin continues to be steady at ~44% * DOCS now penetrated...
Redeye provides an update following CSG’s Q4 2025/2026 report, which showed sales above our estimate...
Redeye updates on Better Collective ahead of Q1-results (due 20 May after market close) where we exp...
* EC IFPM p.s. +7% q-o-q * Renewed mandate for 10% SBBs * 2026e P/CEPS 10x vs.
Redeye provides an update following CLS’s Q1 2026 report.
